Short interest in Polynovo (ASX:PNV) shares is easing. What does this mean?

Is the future looking brighter for Polynovo's stock?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The amount of Polynovo Ltd (ASX: PNV) shares in the hands of short sellers has dropped recently.

Over the week ending 13 December, Polynovo shares had a 7.5% short interest.

However, in The Motley Fool Australia's latest weekly short selling breakdown, the company's short interest had dropped to 7.2%.

At the time of writing, the Polynovo share price is $1.51, 0.2% lower than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is up 0.4% this morning.

Let's take a look at what the company's falling short interest might mean for its long-term investors.

most shorted shares webjet

Image source: Getty Images

What does Polynovo's short interest mean for its shares?

The amount of Polynovo's stock held by short sellers has dipped, and it could spell good news for growth investors.

Short sellers aim to profit from a falling share price. Thus, less short selling activity probably means there's greater confidence in the Polynovo share price among some circles.

Perhaps, the rise in apparent confidence is down to its recent performance.

Over the last 30 days, the company's share price has gained 6.6%, boosted by good news released earlier this month.

Polynovo announced it achieved record sales for July and November on 14 December.

It is also recruiting more sales staff in the United States and its search for a new CEO is progressing well.

Additionally, experts are increasingly bullish on the company's stock.

Macquarie recently upgraded its rating for Polynovo's shares to 'outperform', slapping them with a $2.85 price target. That represents an 88% upside on the company's current share price.

As my Foolish colleague, James Mickleboro, recently reported, the broker believes Polynovo's NovoSorb product will be a major catalyst to its growth.

However, the company still sits among the 10 most shorted shares on the ASX. Potentially, due to the stock's performance through 2021.

Since the start of this year, the Polynovo share price has fallen 61%. It's likely many eyes will be on it in the new year in hopes it can correct its tumble.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares on the slide today?

Big merger news isn't exciting investors just yet.

Read more »

two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market
Healthcare Shares

Down more than 18% in a month with a 7% yield, are Sonic Healthcare shares too cheap to ignore?

This could be a very healthy opportunity to buy.

Read more »

A man in a business suit jumps over a hurdle with a blue sky background.
Healthcare Shares

Why brokers think CSL shares could be on track for $200

CSL needs to tick a lot of boxes, before it can clear the $200 hurdle.

Read more »

Two scientists looking at a tablet.
Healthcare Shares

Telix Pharmaceuticals: ITM merger builds a sector leader

Telix Pharmaceuticals share price is in focus after announcing a transformative merger with ITM, set to expand its radiopharmaceutical pipeline.

Read more »